nodes	percent_of_prediction	percent_of_DWPC	metapath
Abiraterone—ABCC1—Mitoxantrone—lymphatic system cancer	0.251	0.338	CbGbCtD
Abiraterone—ABCC1—Vincristine—lymphatic system cancer	0.172	0.233	CbGbCtD
Abiraterone—ABCC1—Methotrexate—lymphatic system cancer	0.104	0.141	CbGbCtD
Abiraterone—CYP3A4—Cytarabine—lymphatic system cancer	0.0526	0.071	CbGbCtD
Abiraterone—CYP3A4—Teniposide—lymphatic system cancer	0.0518	0.0699	CbGbCtD
Abiraterone—Infectious pneumonitis—Bleomycin—lymphatic system cancer	0.0513	0.198	CcSEcCtD
Abiraterone—ALB—Methotrexate—lymphatic system cancer	0.0482	0.065	CbGbCtD
Abiraterone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0362	0.0489	CbGbCtD
Abiraterone—CYP3A4—Vincristine—lymphatic system cancer	0.0249	0.0336	CbGbCtD
Abiraterone—Lymphopenia—Mechlorethamine—lymphatic system cancer	0.0101	0.039	CcSEcCtD
Abiraterone—Potassium low—Mitoxantrone—lymphatic system cancer	0.00951	0.0367	CcSEcCtD
Abiraterone—Sudden death—Teniposide—lymphatic system cancer	0.00744	0.0288	CcSEcCtD
Abiraterone—Blood potassium decreased—Mitoxantrone—lymphatic system cancer	0.00524	0.0203	CcSEcCtD
Abiraterone—Sudden death—Mitoxantrone—lymphatic system cancer	0.00389	0.015	CcSEcCtD
Abiraterone—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00277	0.0107	CcSEcCtD
Abiraterone—Cardiac failure—Fludarabine—lymphatic system cancer	0.00249	0.00963	CcSEcCtD
Abiraterone—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00248	0.00958	CcSEcCtD
Abiraterone—Contusion—Mitoxantrone—lymphatic system cancer	0.00228	0.00882	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00195	0.00755	CcSEcCtD
Abiraterone—Sudden death—Methotrexate—lymphatic system cancer	0.00194	0.0075	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00191	0.00738	CcSEcCtD
Abiraterone—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00189	0.00732	CcSEcCtD
Abiraterone—Pneumonia—Fludarabine—lymphatic system cancer	0.00188	0.00728	CcSEcCtD
Abiraterone—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00185	0.00714	CcSEcCtD
Abiraterone—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00184	0.0071	CcSEcCtD
Abiraterone—Infection—Mechlorethamine—lymphatic system cancer	0.00183	0.00708	CcSEcCtD
Abiraterone—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00182	0.00704	CcSEcCtD
Abiraterone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00179	0.00692	CcSEcCtD
Abiraterone—Haematuria—Fludarabine—lymphatic system cancer	0.00179	0.0069	CcSEcCtD
Abiraterone—Arrhythmia—Teniposide—lymphatic system cancer	0.00171	0.00661	CcSEcCtD
Abiraterone—Fracture—Methotrexate—lymphatic system cancer	0.00171	0.0066	CcSEcCtD
Abiraterone—Multiple fractures—Methotrexate—lymphatic system cancer	0.00171	0.0066	CcSEcCtD
Abiraterone—Anaemia—Teniposide—lymphatic system cancer	0.00154	0.00595	CcSEcCtD
Abiraterone—Arrhythmia—Fludarabine—lymphatic system cancer	0.0015	0.00581	CcSEcCtD
Abiraterone—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00148	0.00573	CcSEcCtD
Abiraterone—Hypertension—Teniposide—lymphatic system cancer	0.00144	0.00556	CcSEcCtD
Abiraterone—Chest pain—Teniposide—lymphatic system cancer	0.00142	0.00548	CcSEcCtD
Abiraterone—Hypokalaemia—Carmustine—lymphatic system cancer	0.00142	0.00547	CcSEcCtD
Abiraterone—Pneumonia—Bleomycin—lymphatic system cancer	0.00138	0.00534	CcSEcCtD
Abiraterone—Oedema—Teniposide—lymphatic system cancer	0.00136	0.00525	CcSEcCtD
Abiraterone—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00135	0.00523	CcSEcCtD
Abiraterone—Anaemia—Fludarabine—lymphatic system cancer	0.00135	0.00523	CcSEcCtD
Abiraterone—Infection—Teniposide—lymphatic system cancer	0.00135	0.00522	CcSEcCtD
Abiraterone—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00135	0.0052	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00134	0.00517	CcSEcCtD
Abiraterone—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00132	0.00509	CcSEcCtD
Abiraterone—Haematuria—Bleomycin—lymphatic system cancer	0.00131	0.00506	CcSEcCtD
Abiraterone—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.0013	0.00503	CcSEcCtD
Abiraterone—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.00129	0.00497	CcSEcCtD
Abiraterone—Cough—Fludarabine—lymphatic system cancer	0.00128	0.00494	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00128	0.00493	CcSEcCtD
Abiraterone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00126	0.00488	CcSEcCtD
Abiraterone—Myalgia—Fludarabine—lymphatic system cancer	0.00125	0.00482	CcSEcCtD
Abiraterone—Discomfort—Fludarabine—lymphatic system cancer	0.00123	0.00476	CcSEcCtD
Abiraterone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00121	0.00469	CcSEcCtD
Abiraterone—Dyspnoea—Teniposide—lymphatic system cancer	0.00121	0.00468	CcSEcCtD
Abiraterone—Pneumonia—Carmustine—lymphatic system cancer	0.00121	0.00466	CcSEcCtD
Abiraterone—Oedema—Fludarabine—lymphatic system cancer	0.00119	0.00462	CcSEcCtD
Abiraterone—Infection—Fludarabine—lymphatic system cancer	0.00119	0.00459	CcSEcCtD
Abiraterone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00117	0.00453	CcSEcCtD
Abiraterone—Urinary tract infection—Carmustine—lymphatic system cancer	0.00117	0.0045	CcSEcCtD
Abiraterone—Rash—Mechlorethamine—lymphatic system cancer	0.00116	0.00449	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00116	0.00449	CcSEcCtD
Abiraterone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00116	0.00449	CcSEcCtD
Abiraterone—Pneumonia—Vincristine—lymphatic system cancer	0.00115	0.00445	CcSEcCtD
Abiraterone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00113	0.00436	CcSEcCtD
Abiraterone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00436	CcSEcCtD
Abiraterone—Myocardial infarction—Vincristine—lymphatic system cancer	0.00112	0.00434	CcSEcCtD
Abiraterone—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00112	0.00433	CcSEcCtD
Abiraterone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0011	0.00425	CcSEcCtD
Abiraterone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00109	0.00422	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00109	0.00421	CcSEcCtD
Abiraterone—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00108	0.00419	CcSEcCtD
Abiraterone—Body temperature increased—Teniposide—lymphatic system cancer	0.00107	0.00415	CcSEcCtD
Abiraterone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00106	0.00412	CcSEcCtD
Abiraterone—Haematuria—Mitoxantrone—lymphatic system cancer	0.00106	0.00411	CcSEcCtD
Abiraterone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00106	0.00409	CcSEcCtD
Abiraterone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00105	0.00406	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00103	0.00399	CcSEcCtD
Abiraterone—Fatigue—Fludarabine—lymphatic system cancer	0.00103	0.00398	CcSEcCtD
Abiraterone—Constipation—Fludarabine—lymphatic system cancer	0.00102	0.00395	CcSEcCtD
Abiraterone—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00101	0.00392	CcSEcCtD
Abiraterone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00101	0.0039	CcSEcCtD
Abiraterone—Urethral disorder—Vincristine—lymphatic system cancer	0.00101	0.00389	CcSEcCtD
Abiraterone—Anaemia—Bleomycin—lymphatic system cancer	0.000992	0.00383	CcSEcCtD
Abiraterone—Asthenia—Teniposide—lymphatic system cancer	0.000975	0.00377	CcSEcCtD
Abiraterone—Arrhythmia—Carmustine—lymphatic system cancer	0.000961	0.00372	CcSEcCtD
Abiraterone—Cardiac disorder—Vincristine—lymphatic system cancer	0.000953	0.00368	CcSEcCtD
Abiraterone—Body temperature increased—Fludarabine—lymphatic system cancer	0.000944	0.00365	CcSEcCtD
Abiraterone—Mental disorder—Carmustine—lymphatic system cancer	0.000943	0.00364	CcSEcCtD
Abiraterone—Cough—Bleomycin—lymphatic system cancer	0.000936	0.00362	CcSEcCtD
Abiraterone—Angiopathy—Vincristine—lymphatic system cancer	0.000932	0.0036	CcSEcCtD
Abiraterone—Diarrhoea—Teniposide—lymphatic system cancer	0.00093	0.00359	CcSEcCtD
Abiraterone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000926	0.00358	CcSEcCtD
Abiraterone—Chest pain—Bleomycin—lymphatic system cancer	0.000914	0.00353	CcSEcCtD
Abiraterone—Myalgia—Bleomycin—lymphatic system cancer	0.000914	0.00353	CcSEcCtD
Abiraterone—Discomfort—Bleomycin—lymphatic system cancer	0.000903	0.00349	CcSEcCtD
Abiraterone—Mental disorder—Vincristine—lymphatic system cancer	0.0009	0.00348	CcSEcCtD
Abiraterone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000894	0.00345	CcSEcCtD
Abiraterone—Oedema—Bleomycin—lymphatic system cancer	0.000876	0.00339	CcSEcCtD
Abiraterone—Infection—Bleomycin—lymphatic system cancer	0.00087	0.00336	CcSEcCtD
Abiraterone—Anaemia—Carmustine—lymphatic system cancer	0.000866	0.00335	CcSEcCtD
Abiraterone—Vomiting—Teniposide—lymphatic system cancer	0.000864	0.00334	CcSEcCtD
Abiraterone—Asthenia—Fludarabine—lymphatic system cancer	0.000857	0.00331	CcSEcCtD
Abiraterone—Rash—Teniposide—lymphatic system cancer	0.000857	0.00331	CcSEcCtD
Abiraterone—Dermatitis—Teniposide—lymphatic system cancer	0.000856	0.00331	CcSEcCtD
Abiraterone—Anaemia—Vincristine—lymphatic system cancer	0.000826	0.00319	CcSEcCtD
Abiraterone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000817	0.00316	CcSEcCtD
Abiraterone—Hypertension—Carmustine—lymphatic system cancer	0.000809	0.00313	CcSEcCtD
Abiraterone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000805	0.00311	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000798	0.00308	CcSEcCtD
Abiraterone—Myalgia—Carmustine—lymphatic system cancer	0.000797	0.00308	CcSEcCtD
Abiraterone—Chest pain—Carmustine—lymphatic system cancer	0.000797	0.00308	CcSEcCtD
Abiraterone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000781	0.00302	CcSEcCtD
Abiraterone—Hypertension—Vincristine—lymphatic system cancer	0.000772	0.00298	CcSEcCtD
Abiraterone—Oedema—Carmustine—lymphatic system cancer	0.000764	0.00295	CcSEcCtD
Abiraterone—Myalgia—Vincristine—lymphatic system cancer	0.000761	0.00294	CcSEcCtD
Abiraterone—Cough—Mitoxantrone—lymphatic system cancer	0.00076	0.00294	CcSEcCtD
Abiraterone—Infection—Carmustine—lymphatic system cancer	0.000759	0.00294	CcSEcCtD
Abiraterone—Vomiting—Fludarabine—lymphatic system cancer	0.000759	0.00294	CcSEcCtD
Abiraterone—Rash—Fludarabine—lymphatic system cancer	0.000753	0.00291	CcSEcCtD
Abiraterone—Dermatitis—Fludarabine—lymphatic system cancer	0.000752	0.00291	CcSEcCtD
Abiraterone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000752	0.00291	CcSEcCtD
Abiraterone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000741	0.00287	CcSEcCtD
Abiraterone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000741	0.00287	CcSEcCtD
Abiraterone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000732	0.00283	CcSEcCtD
Abiraterone—Oedema—Vincristine—lymphatic system cancer	0.00073	0.00282	CcSEcCtD
Abiraterone—Infection—Vincristine—lymphatic system cancer	0.000725	0.0028	CcSEcCtD
Abiraterone—Oedema—Mitoxantrone—lymphatic system cancer	0.000711	0.00275	CcSEcCtD
Abiraterone—Infection—Mitoxantrone—lymphatic system cancer	0.000706	0.00273	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000697	0.00269	CcSEcCtD
Abiraterone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000692	0.00268	CcSEcCtD
Abiraterone—Insomnia—Carmustine—lymphatic system cancer	0.000691	0.00267	CcSEcCtD
Abiraterone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00069	0.00267	CcSEcCtD
Abiraterone—Dyspnoea—Carmustine—lymphatic system cancer	0.000682	0.00263	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000665	0.00257	CcSEcCtD
Abiraterone—Insomnia—Vincristine—lymphatic system cancer	0.00066	0.00255	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00066	0.00255	CcSEcCtD
Abiraterone—Constipation—Carmustine—lymphatic system cancer	0.000654	0.00253	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000648	0.0025	CcSEcCtD
Abiraterone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000634	0.00245	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00063	0.00244	CcSEcCtD
Abiraterone—Fatigue—Vincristine—lymphatic system cancer	0.000629	0.00243	CcSEcCtD
Abiraterone—Asthenia—Bleomycin—lymphatic system cancer	0.000628	0.00243	CcSEcCtD
Abiraterone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000626	0.00242	CcSEcCtD
Abiraterone—Constipation—Vincristine—lymphatic system cancer	0.000624	0.00241	CcSEcCtD
Abiraterone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000613	0.00237	CcSEcCtD
Abiraterone—Constipation—Mitoxantrone—lymphatic system cancer	0.000608	0.00235	CcSEcCtD
Abiraterone—Body temperature increased—Carmustine—lymphatic system cancer	0.000604	0.00234	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000579	0.00224	CcSEcCtD
Abiraterone—Body temperature increased—Vincristine—lymphatic system cancer	0.000577	0.00223	CcSEcCtD
Abiraterone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000562	0.00217	CcSEcCtD
Abiraterone—Pneumonia—Methotrexate—lymphatic system cancer	0.000558	0.00216	CcSEcCtD
Abiraterone—Vomiting—Bleomycin—lymphatic system cancer	0.000557	0.00215	CcSEcCtD
Abiraterone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000555	0.00215	CcSEcCtD
Abiraterone—Infestation—Methotrexate—lymphatic system cancer	0.000555	0.00215	CcSEcCtD
Abiraterone—Rash—Bleomycin—lymphatic system cancer	0.000552	0.00213	CcSEcCtD
Abiraterone—Dermatitis—Bleomycin—lymphatic system cancer	0.000552	0.00213	CcSEcCtD
Abiraterone—Asthenia—Carmustine—lymphatic system cancer	0.000548	0.00212	CcSEcCtD
Abiraterone—Haematuria—Methotrexate—lymphatic system cancer	0.000529	0.00205	CcSEcCtD
Abiraterone—Asthenia—Vincristine—lymphatic system cancer	0.000524	0.00202	CcSEcCtD
Abiraterone—Diarrhoea—Carmustine—lymphatic system cancer	0.000523	0.00202	CcSEcCtD
Abiraterone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00051	0.00197	CcSEcCtD
Abiraterone—Diarrhoea—Vincristine—lymphatic system cancer	0.000499	0.00193	CcSEcCtD
Abiraterone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000492	0.0019	CcSEcCtD
Abiraterone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000489	0.00189	CcSEcCtD
Abiraterone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000486	0.00188	CcSEcCtD
Abiraterone—Vomiting—Carmustine—lymphatic system cancer	0.000486	0.00188	CcSEcCtD
Abiraterone—Rash—Carmustine—lymphatic system cancer	0.000482	0.00186	CcSEcCtD
Abiraterone—Dermatitis—Carmustine—lymphatic system cancer	0.000482	0.00186	CcSEcCtD
Abiraterone—Vomiting—Vincristine—lymphatic system cancer	0.000464	0.00179	CcSEcCtD
Abiraterone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000463	0.00179	CcSEcCtD
Abiraterone—Rash—Vincristine—lymphatic system cancer	0.00046	0.00178	CcSEcCtD
Abiraterone—Dermatitis—Vincristine—lymphatic system cancer	0.00046	0.00178	CcSEcCtD
Abiraterone—Angiopathy—Methotrexate—lymphatic system cancer	0.000452	0.00175	CcSEcCtD
Abiraterone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000452	0.00175	CcSEcCtD
Abiraterone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000449	0.00174	CcSEcCtD
Abiraterone—Rash—Mitoxantrone—lymphatic system cancer	0.000448	0.00173	CcSEcCtD
Abiraterone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000448	0.00173	CcSEcCtD
Abiraterone—Mental disorder—Methotrexate—lymphatic system cancer	0.000437	0.00169	CcSEcCtD
Abiraterone—Anaemia—Methotrexate—lymphatic system cancer	0.000401	0.00155	CcSEcCtD
Abiraterone—Cough—Methotrexate—lymphatic system cancer	0.000379	0.00146	CcSEcCtD
Abiraterone—Myalgia—Methotrexate—lymphatic system cancer	0.000369	0.00143	CcSEcCtD
Abiraterone—Chest pain—Methotrexate—lymphatic system cancer	0.000369	0.00143	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000367	0.00142	CcSEcCtD
Abiraterone—Discomfort—Methotrexate—lymphatic system cancer	0.000365	0.00141	CcSEcCtD
Abiraterone—Infection—Methotrexate—lymphatic system cancer	0.000352	0.00136	CcSEcCtD
Abiraterone—Skin disorder—Methotrexate—lymphatic system cancer	0.000344	0.00133	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000323	0.00125	CcSEcCtD
Abiraterone—Insomnia—Methotrexate—lymphatic system cancer	0.00032	0.00124	CcSEcCtD
Abiraterone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000316	0.00122	CcSEcCtD
Abiraterone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000312	0.0012	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000306	0.00118	CcSEcCtD
Abiraterone—Fatigue—Methotrexate—lymphatic system cancer	0.000305	0.00118	CcSEcCtD
Abiraterone—Body temperature increased—Methotrexate—lymphatic system cancer	0.00028	0.00108	CcSEcCtD
Abiraterone—Asthenia—Methotrexate—lymphatic system cancer	0.000254	0.000982	CcSEcCtD
Abiraterone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000242	0.000936	CcSEcCtD
Abiraterone—Vomiting—Methotrexate—lymphatic system cancer	0.000225	0.00087	CcSEcCtD
Abiraterone—Rash—Methotrexate—lymphatic system cancer	0.000223	0.000863	CcSEcCtD
Abiraterone—Dermatitis—Methotrexate—lymphatic system cancer	0.000223	0.000862	CcSEcCtD
